SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting drives immense volume and its Crypto.com partnership expands prediction markets, while the community actively debates whether emerging unregulated prediction platforms pose a significant threat ahead of next week's anticipated earnings.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending following its decision to pull a newly launched compounded weight-loss pill due to regulatory pressure and legal threats. This move has sparked debate, with some viewing it as a significant setback while others believe it strategically removes a legal overhang and positions the core telehealth platform for a rebound, amplified by its Super Bowl ad.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending following a significant Super Bowl commercial featuring Christina Applegate for its Briumvi multiple sclerosis drug, which the community views as a powerful boost for brand visibility and patient confidence. This marketing success, combined with growing discussion over a competitor's drug (Fenebrutinib) and its potential liver toxicity concerns, is intensifying conversation around Briumvi's market leadership and long-term value.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending after announcing a $250 million financing amendment, extending its capital runway through 2028, which bulls anticipate will fuel a historic short squeeze given its low float and past parabolic runs. However, community discussion also highlights concerns about potential dilution from the equity line of credit amidst the company's current lack of revenue generation.

JERRY (JYAI) is a Matt Furie's artistic style; it features an AI-powered content creation hub that produces community-driven video series and art.  Jerry the Turtle, created by Matt Furie, is a character inspired by Furie’s artistic style. JERRY is also an AI-driven meme coin with an ambitious vision. The goal is to establish an AI-powered production house dedicated to creating a video series or episodes featuring characters from Matt Furie’s universe alongside those from Jerry’s world.  This unique blend of characters aims to produce the ultimate crypto-based series. Additionally, we are developing an app that will offer an exclusive, ad-free video series featuring characters from both Matt Furie’s creations and the Jerry Universe. Users will be able to download and share videos directly through the platform.  But that’s not all! A special Jerry Art Panel will showcase original Jerry characters, artwork, and fan creations—free to explore, download, and share with the community.

Jerry The Turtle By Matt Furie

JYAI CRYPTO is trending as community anticipation builds around its confirmed Tier 1 exchange listings and recent debut on platforms like KuCoin Alpha and Bitget. Enthusiasts are actively comparing it to early successful memecoins, fueled by its aggressive 12-week marketing initiative and developer updates.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap (UNI) is trending as its community overwhelmingly supports a game-changing governance proposal to activate a fee switch and implement a significant token burn, aiming to align the protocol's high fee generation with UNI's value and establish deflationary tokenomics.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as strong institutional accumulation and anticipation of a potential Chronoscale spinoff fuel bullish sentiment, with the community highlighting the company's growing contracted revenue pipeline and strategic position to capitalize on massive hyperscaler capital expenditures for AI infrastructure, despite recent market volatility.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is experiencing a strong rally fueled by a resurgence in M&A activity, highlighted by recent acquisitions and numerous buyout rumors as major pharmaceutical companies actively seek to replenish pipelines ahead of patent cliffs. The community is buzzing about a "BioWar" and the sector's perceived undervaluation, with optimism further boosted by positive individual drug developments.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is making strong gains, reaching recent highs following several analyst upgrades and a dividend increase, driven by robust international growth and new value menu initiatives. The community views it as a resilient defensive play, attracting capital amidst broader market uncertainty, despite ongoing debates about menu affordability and pricing for consumers.

Investment Managers Series Trust II - Tradr 2X Long APLD Daily ETF

Tradr 2X Long APLD Daily ETF

APLX is trending due to significant magnified gains from the underlying APLD's strong performance in the AI and data center sectors, with the community actively discussing its "parabolic" moves and potential for quick profits, while also acknowledging the amplified volatility and risks inherent in this 2x leveraged ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>China granted Priority Review for an at-home Alzheimer’s treatment developed by Biogen and Eisai.</li><li>If approved, the subcutaneous version would allow once-weekly at-home&nbsp;dosing instead of biweekly hospital IV infusions.</li><li>Analysts also raised price targets following Biogen’s Q4 earnings beat.</li></ul>Shares of Biogen (BIIB) drew heightened retail chatter late Sunday after the company and partner Eisai said China’s drug regulator granted Priority Review to a subcutaneous formulation of Leqembi for the treatment of early Alzheimer’s disease.<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> jumped 9% on Friday to close at $201.18, marking its highest level in more than 16 months and its best session in over four months.<h2 class="st-heading-2">Leqembi At-Home Dosing</h2>If approved, the subcutaneous formulation would enable once-weekly at-home dosing, rather than the intravenous dosing administered every two weeks at the hospital under the current regimen. The companies noted that each autoinjector delivers a 250 mg dose in about 15 seconds, requiring two injections per weekly dose.&nbsp;Leqembi was launched in China in 2024 and was added to the country’s Commercial Insurance Innovative Drug List effective January 2026, under policies supporting access to innovative medicines. Eisai leads global development and regulatory submissions for Leqembi, and it and Biogen co-commercialize the product.<h2 class="st-heading-2">Analysts Raise Targets After Q4 Results</h2>Biogen also saw a wave of target hikes following its fourth-quarter (Q4) earnings report.Wells Fargo raised its price target to $200 from $190, implying a 0.6% downside from its last close and kept an 'Equal Weight' rating, saying it expects the company’s 2026 launch execution to remain steady and that near-term late-stage catalysts could improve the outlook toward the end of the decade.&nbsp;Bank of America lifted its price target to $207 from $189, implying a 3% upside from current levels, and maintained a 'Neutral' rating, attributing the post-earnings share rally to what it called “clear positives” from the earnings call, including “not as bad as feared erosion” of the multiple sclerosis franchise.&nbsp;Morgan Stanley raised its price target to $190 from $156, implying a 6% downside from current levels, and kept an 'Equal Weight' rating, saying the company’s “building” pipeline is now the focus following the Q4 report.&nbsp;Citi increased its price target to $215 from $185, implying a 7% upside from last close, and reiterated a 'Neutral' rating, saying it views the Q4 report as solid and remains optimistic about Biogen’s ability to launch new products and develop its pipeline.&nbsp;BMO Capital raised its price target to $196 from $165, implying a 3% downside from its last close, and kept a 'Market Perform' rating. The firm said revenue erosion from the multiple sclerosis business is expected to continue in 2026, but added it is growing more confident in the long-term opportunity for high-dose Spinraza and upcoming Litifilimab readouts in systemic lupus erythematosus.&nbsp;<h2 class="st-heading-2">BIIB Q4 Earnings</h2>Biogen reported Q4 adjusted earnings per share (EPS) of $1.99, above consensus expectations of $1.63, on revenue of $2.3 billion, compared with a $2.2 billion consensus.&nbsp;For full-year 2026, the company guided to adjusted EPS of $15.25–$16.25, above the consensus estimate of $14.95, and forecast revenue to decline mid-single digits versus 2025. Biogen also said its adjusted effective tax rate for 2026 is expected to be 17%–18%, with gross margin and combined non-GAAP research and development (R&amp;D) and administrative expenses roughly consistent year over year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for BIIB was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/biib_ss_png_61b28cbdcd.webp" alt="biib ss.png" width="971" height="142"><figcaption>BIIB sentiment and message volume as of February 8 | Source: Stocktwits</figcaption></figure>One user said the stock stands out as a “high-quality large-cap biotech with real optionality,” citing a strong balance sheet, durable cash flows from its core neurology franchise, and multiple shots on goal across Alzheimer’s, depression, and rare neuro diseases.<stembedurl>https://stocktwits.com/MoleculeHunterX/message/644276931</stembedurl>Another user said, “feel like we should be over $200 already 210 or so. Hopefully this keeps momentum and goes to $220”<stembedurl>https://stocktwits.com/gratefultobe/message/644236362</stembedurl>BIIB stock has risen 41% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi

Analyst price targets for BIIB are in the range of $190 to $215, implying a downside of about 6% to an upside of nearly 7% from the last close.

Equity

Twin Capital Management Inc. Sells 5,246 Shares of Biogen Inc. $BIIB

Twin Capital Management Inc. decreased its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 43.6% in the third quarter, according to the company in its most recent 13F filing with the...

Penserra Capital Management LLC Has $706,000 Holdings in Biogen Inc. $BIIB

Penserra Capital Management LLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 41,941.7% during the third quarter, according to its most recent 13F filing with the SEC. The...

Stifel Nicolaus Increases Biogen (NASDAQ:BIIB) Price Target to $214.00

Stifel Nicolaus lifted their price objective on shares of Biogen from $202.00 to $214.00 and gave the company a "buy" rating in a research note on Friday...

Why Biogen Stock Surged Almost 9% Higher on Friday

Key PointsThe biotech published its last set of financials for 2025...

Biogen (NASDAQ:BIIB) Posts Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Biogen (NASDAQ:BIIB - Get Free Report) issued its earnings results on Friday. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.72 by...

BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View

Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.

Pre-Markets Open in Green to Close the Week

Pre-Markets Open in Green to Close the Week.

Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump

Biogen beat fourth-quarter earnings and revenue estimates as growth from Leqembi, Skyclarys, and Zurzuvae offset declining multiple sclerosis sales, while the company forecast higher 2026...

Pre-Markets Rebounding Ahead of Super Bowl Sunday

We're seeing is a slight uptick at this hour for companies like Draft Kings (DKNG) and FanDuel parent Flutter (FLUT).

$BIIB Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.33 down -118.03% YoY
• Reported revenue of $2.28B down -7.14% YoY
• Biogen expects full year 2026 Non-GAAP diluted EPS to be between $15.25 and $16.25. Total revenue is anticipated to decline by a mid-single digit percentage compared to full year 2025.

Stocktwits

Biogen Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.33 down -118.03% YoY
• Reported revenue of $2.28B down -7.14% YoY
• Biogen expects full year 2026 Non-GAAP diluted EPS to be between $15.25 and $16.25. Total revenue is anticipated to decline by a mid-single digit percentage compared to full year 2025.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

What will be the S&P 500’s next 5% move?

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$3.28	--	--	N/A
Q4 '25	$1.63	$1.99	22.45%	BEAT
Q3 '25	$3.88	$4.81	23.89%	BEAT
Q2 '25	$3.90	$5.47	40.38%	BEAT
Q1 '25	$2.90	$3.02	4.16%	BEAT

BIIB
Biogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest BIIB News

BIIBBiogen Inc